New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures

Adam L Boxer¹, Michael Gold², Howard Feldman³, Bradley F Boeve⁴, Susan L-J Dickinson⁵, Howard Fillit⁶, Carole Ho⁷, Robert Paul⁸, Rodney Pearlman⁹, Margaret Sutherland¹⁰, Ajay Verma¹¹, Stephen P Arneric¹², Brian M Alexander¹³, Bradford C Dickerson¹⁴, Earl Ray Dorsey¹⁵, Murray Grossman¹⁶, Edward D Huey¹⁷, Michael C Irizarry¹⁸, William J Marks¹⁹, Mario Masellis^{20

21}, Frances McFarland²², Debra Niehoff⁵, Chiadi U Onyike²³, Sabrina Paganoni²⁴, Michael A Panzara²⁵, Kenneth Rockwood²⁶, Jonathan D Rohrer²⁷, Howard Rosen¹, Robert N Schuck²⁸, Holly D Soares²⁹, Nadine Tatton⁵

Affiliations

¹ Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
² Development Neurosciences, AbbVie, Chicago, IL, USA.
³ Department of Neurosciences, University of California San Diego, San Diego, CA, USA.
⁴ Department of Neurology, Mayo Clinic, Rochester, MN, USA.
⁵ Association for Frontotemporal Degeneration, Radnor, PA, USA.
⁶ Alzheimer's Drug Discovery Foundation, New York, NY, USA.
⁷ Denali Therapeutics, San Francisco, CA, USA.
⁸ Alector, Inc., South San Francisco, CA, USA.
⁹ The Bluefield Project, San Francisco, CA, USA.
¹⁰ Chan Zuckerberg Initiative, Redwood City, CA, USA.
¹¹ United Neuroscience, Dublin, Ireland.
¹² Critical Path Institute, Tucson, AZ, USA.
¹³ Dana-Farber Cancer Institute, Harvard University, Boston, MA, USA.
¹⁴ Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.
¹⁵ Center for Health and Technology, University of Rochester, Rochester, NY, USA.
¹⁶ Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA.
¹⁷ Departments of Psychiatry and Neurology, Columbia University, NY, USA.
¹⁸ Formerly of Early Phase Neurosciences, Eli Lilly, Indianapolis, IN, USA.
¹⁹ Clinical Neurology, Verily Life Sciences, South San Francisco, CA, USA.
²⁰ Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, University of Toronto, ON, Canada.
²¹ Department of Medicine (Neurology), Sunnybrook Health Sciences Centre, University of Toronto, ON, Canada.
²² McFarland Writing, Annapolis, MD, USA.
²³ Department Geriatric Psychiatry and Neuropsychiatry, Johns Hopkins University, Baltimore, MD, USA.
²⁴ Healey Center for ALS, Massachusetts General Hospital, Boston, MA, USA.
²⁵ Development, Wave Life Sciences, Boston, MA, USA.
²⁶ Division of Geriatric Medicine, Dalhousie University, Halifax, NS, Canada.
²⁷ Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, UK.
²⁸ Office of Clinical Pharmacology, Center for Drug Evaluation and Research, FDA, Silver Spring, MD, USA.
²⁹ Department of Neurology, AbbVie, Chicago, IL, USA.

PMID: 31668596
PMCID: PMC6949386
DOI: 10.1016/j.jalz.2019.06.4956

New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures

Adam L Boxer et al. Alzheimers Dement. 2020 Jan.

. 2020 Jan;16(1):131-143.

doi: 10.1016/j.jalz.2019.06.4956. Epub 2020 Jan 6.

Authors

Affiliations

¹ Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
² Development Neurosciences, AbbVie, Chicago, IL, USA.
³ Department of Neurosciences, University of California San Diego, San Diego, CA, USA.
⁴ Department of Neurology, Mayo Clinic, Rochester, MN, USA.
⁵ Association for Frontotemporal Degeneration, Radnor, PA, USA.
⁶ Alzheimer's Drug Discovery Foundation, New York, NY, USA.
⁷ Denali Therapeutics, San Francisco, CA, USA.
⁸ Alector, Inc., South San Francisco, CA, USA.
⁹ The Bluefield Project, San Francisco, CA, USA.
¹⁰ Chan Zuckerberg Initiative, Redwood City, CA, USA.
¹¹ United Neuroscience, Dublin, Ireland.
¹² Critical Path Institute, Tucson, AZ, USA.
¹³ Dana-Farber Cancer Institute, Harvard University, Boston, MA, USA.
¹⁴ Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.
¹⁵ Center for Health and Technology, University of Rochester, Rochester, NY, USA.
¹⁶ Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA.
¹⁷ Departments of Psychiatry and Neurology, Columbia University, NY, USA.
¹⁸ Formerly of Early Phase Neurosciences, Eli Lilly, Indianapolis, IN, USA.
¹⁹ Clinical Neurology, Verily Life Sciences, South San Francisco, CA, USA.
²⁰ Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, University of Toronto, ON, Canada.
²¹ Department of Medicine (Neurology), Sunnybrook Health Sciences Centre, University of Toronto, ON, Canada.
²² McFarland Writing, Annapolis, MD, USA.
²³ Department Geriatric Psychiatry and Neuropsychiatry, Johns Hopkins University, Baltimore, MD, USA.
²⁴ Healey Center for ALS, Massachusetts General Hospital, Boston, MA, USA.
²⁵ Development, Wave Life Sciences, Boston, MA, USA.
²⁶ Division of Geriatric Medicine, Dalhousie University, Halifax, NS, Canada.
²⁷ Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, UK.
²⁸ Office of Clinical Pharmacology, Center for Drug Evaluation and Research, FDA, Silver Spring, MD, USA.
²⁹ Department of Neurology, AbbVie, Chicago, IL, USA.

PMID: 31668596
PMCID: PMC6949386
DOI: 10.1016/j.jalz.2019.06.4956

Abstract

Introduction: Frontotemporal lobar degeneration (FTLD) is the most common form of dementia for those under 60 years of age. Increasing numbers of therapeutics targeting FTLD syndromes are being developed.

Methods: In March 2018, the Association for Frontotemporal Degeneration convened the Frontotemporal Degeneration Study Group meeting in Washington, DC, to discuss advances in the clinical science of FTLD.

Results: Challenges exist for conducting clinical trials in FTLD. Two of the greatest challenges are (1) the heterogeneity of FTLD syndromes leading to difficulties in efficiently measuring treatment effects and (2) the rarity of FTLD disorders leading to recruitment challenges.

Discussion: New personalized endpoints that are clinically meaningful to individuals and their families should be developed. Personalized approaches to analyzing MRI data, development of new fluid biomarkers and wearable technologies will help to improve the power to detect treatment effects in FTLD clinical trials and enable new, clinical trial designs, possibly leveraged from the experience of oncology trials. A computational visualization and analysis platform that can support novel analyses of combined clinical, genetic, imaging, biomarker data with other novel modalities will be critical to the success of these endeavors.

Keywords: ARTFL; Biomarker; C9orf72; Clinical trial; FTD; FTLD; Frontotemporal dementia; Frontotemporal lobar degeneration; GRN; LEFFTDS; MAPT; Primary progressive aphasia; Progressive supranuclear palsy.

PubMed Disclaimer

References

1. Jicha GA, Nelson PT. Management of frontotemporal dementia: targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options. Neurodegenerative disease management. 2011;1:141–56. - PMC - PubMed
1. Boxer AL, Gold M, Huey E, Gao FB, Burton EA, Chow T, et al. Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2013;9:176–88. - PMC - PubMed
1. Tsai RM, Boxer AL. Therapy and clinical trials in frontotemporal dementia: past, present, and future. Journal of neurochemistry. 2016;138 Suppl 1:211–21. - PMC - PubMed
1. Hodges JR, Piguet O. Progress and Challenges in Frontotemporal Dementia Research: A 20-Year Review. Journal of Alzheimer's disease : JAD. 2018;62:1467–80. - PMC - PubMed
1. O'Connor CM, Clemson L, Hornberger M, Leyton CE, Hodges JR, Piguet O, et al. Longitudinal change in everyday function and behavioral symptoms in frontotemporal dementia. Neurology Clinical practice. 2016;6:419–28. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- H1 Connect - Access expert opinions and insights on biomedical research.
- The Lens - Patent Citations Database
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures

Affiliations

New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures

Authors

Affiliations

Abstract

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous